BCZ

3-(1-ACETYLAMINO-2-ETHYL-BUTYL)-4-GUANIDINO-2-HYDROXY-CYCLOPENTANECARBOXYLIC ACID

Created:	2002-03-18
Last modified:	2020-06-05

Find Related PDB Entry
11 entries where BCZ is found as a standalone ligand

Help Find related ligands:
Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Help

Find related ligands:

Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	51
Chiral Atom Count	5
Bond Count	51
Aromatic Bond Count	0

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	3-(1-ACETYLAMINO-2-ETHYL-BUTYL)-4-GUANIDINO-2-HYDROXY-CYCLOPENTANECARBOXYLIC ACID
Synonyms	BCX-1812
Systematic Name (OpenEye OEToolkits)	(1S,2S,3R,4R)-3-[(1S)-1-acetamido-2-ethyl-butyl]-4-carbamimidamido-2-hydroxy-cyclopentane-1-carboxylic acid
Formula	C₁₅ H₂₈ N₄ O₄
Molecular Weight	328.407
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	ACDLabs	10.04	O=C(O)C1CC(NC(=[N@H])N)C(C(NC(=O)C)C(CC)CC)C1O
SMILES	CACTVS	3.341	CCC(CC)[CH](NC(C)=O)[CH]1[CH](O)[CH](C[CH]1NC(N)=N)C(O)=O
SMILES	OpenEye OEToolkits	1.5.0	CCC(CC)C(C1C(CC(C1O)C(=O)O)NC(=N)N)NC(=O)C
Canonical SMILES	CACTVS	3.341	CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O
Canonical SMILES	OpenEye OEToolkits	1.5.0	CCC(CC)[C@@H]([C@H]1[C@@H](C[C@@H]([C@H]1O)C(=O)O)NC(=N)N)NC(=O)C
InChI	InChI	1.03	InChI=1S/C15H28N4O4/c1-4-8(5-2)12(18-7(3)20)11-10(19-15(16)17)6-9(13(11)21)14(22)23/h8-13,21H,4-6H2,1-3H3,(H,18,20)(H,22,23)(H4,16,17,19)/t9-,10+,11+,12-,13+/m0/s1
InChIKey	InChI	1.03	XRQDFNLINLXZLB-CKIKVBCHSA-N

Drug Info: DrugBank

DrugBank ID	DB06614
Name	Peramivir
Groups	approved investigational
Description	Peramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B. The development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic. Being an influenza virus neuraminidase inhibitor, peramivir works by preventing new viruses from emerging from infected cells. Due to the poor oral bioavailability, the oral formulation of the drug was previously abandoned by Johnson and Johnson Company. The injectable intravenous formulation of peramivir was approved by the FDA in September 2017 for the treatment of acute uncomplicated influenza to pediatric patients 2 years and older who have been symptomatic for no more than two days.
Synonyms	Peramivir Peramivir hydrate Peramivir anhydrous
Brand Names	Alpivab Rapivab
Indication	Peramivir is indicated for the treatment of acute uncomplicated influenza in patients six months and older who have been symptomatic for no more than two days.[L36768]
Categories	Amidines Anti-Infective Agents Antiinfectives for Systemic Use Antiviral Agents Antivirals for Systemic Use Direct Acting Antivirals Enzyme Inhibitors Neuraminidase Inhibitors Neuraminidase, antagonists & inhibitors
ATC-Code	J05AH03
CAS number	330600-85-6

Drug Targets

Name	Target Sequence	Pharmacological Action
Neuraminidase	MNPNQKILCTSATALVIGTIAVLIGITNLGLNIGLHLKPSCNCSHSQPEA...	unknown
Neuraminidase	MNPNQKIITIGSVSLTIATICFLMQIAILVTTVTLHFKQYECSSPPNNQV...	unknown
Neuraminidase	MLPSTIQTLTLFLTSGGVLLSLYVSASLSYLLYSDILLKFSSKITAPTMT...	unknown

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682